Hepatitis, Hepatitis C, Digestive System Diseases, Flaviviridae Infections, Hepatitis, Viral, Human, Liver Diseases, RNA Virus Infections, Virus Diseases
Conditions
Brief summary
This is a randomized, multicenter, 2-part, open-label trial of the combination regimen of grazoprevir (GZR \[MK-5172\]; 100mg), uprifosbuvir (UPR \[MK-3682\]; 450 mg) and ruzasvir (RZR \[MK-8408\]; 60 mg) with and without Ribavirin (RBV) in cirrhotic (C) or non-cirrhotic (NC) participants infected with hepatitis C virus (HCV) previously failing a direct-acting antiviral regimen (DAA). The combination regimen, referred to as MK-3682B, will be administered as two fixed-dose combination (FDC) tablets, given once-daily. The study will evaluate the efficacy of MK-3682B with or without RBV as assessed by the proportion of participants achieving Sustained Virologic Response 12 weeks (SVR12) after the end of all study therapy.
Detailed description
This trial was divided into Part A and Part B. In Part A, comprised of 4 treatment arms, C or NC participants with HCV genotype (GT) 1 infection previously failing a DAA regimen of either sofosbuvir (SOF)/ledipasvir (LDV) \[Arms 1 and 2\] or elbasvir (EBR)/GZR \[Arms 3 and 4\] were randomized to receive either one of the following: 1) MK-3682B + RBV for 16 weeks \[Arms 1 and 3\]; or 2) MK-3682B for 24 weeks \[Arms 2 and 4\]. Study Part A was completed as planned per study protocol. In Part B, C or NC participants with GT1 through GT6 infection previously failing any all-oral DAA regimen (GT1-6) or SOF/pegylated interferon and ribavirin (PR) regimen (GT 3 only) were to receive MK-3682B for 16 weeks. However, the trial was terminated prior to participant enrollment for study Part B. Participants in MK-5172-017 (NCT01667081) were eligible for enrollment in the study.
Interventions
DRUGMK-3682B
Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
DRUGRibavirin
Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Part A * Has documented chronic HCV GT1 or HCV GT3 infection with no evidence of non-typeable or mixed genotype. * Has documented relapse, defined as having HCV RNA target not detected at end-of-treatment, but HCV RNA quantifiable during follow-up, after treatment with one of the following DAA regimens either by approved dosage and duration or by completion of a clinical trial: GT1: SOF/LDV ± RBV; GT1: GZR/EBR ± RBV; GT3: SOF + RBV; GT3: SOF + PR; GT3: SOF + DCV ± RBV; GT3: SOF/LDV ± RBV. * Is otherwise healthy. * If male, be not of reproductive potential or agree to avoid impregnating a partner beginning at least 2 weeks prior to administration of the initial dose of study drug, through 6 months after taking the last dose of study drug (or longer if dictated by local regulations), by complying with one of the following: (1) practice abstinence from heterosexual activity or (2) use (or have their partner use) two forms of acceptable contraception during heterosexual activity which may include oral contraceptives. Part B * Has documented chronic HCV GT1, GT2, GT3, GT4, GT5, GT6 infection with no evidence of non-typeable or mixed genotype. * Has documented virologic failure, defined as having quantifiable HCV RNA at any time after completion of HCV therapy with a DAA regimen either by approved dosage and duration or by completion of a clinical trial that was not attributed to re-infection: GT1, GT2, GT4, GT5, or GT6: any prior all-oral DAA regimens; GT3: any prior all-oral DAA regimen or SOF/PR. Participants \[Parts A and B\] who previously failed PR treatment, with or without simepravir (SIM), boceprevir (BOC), or telaprevir (TPV), prior to receiving DAA therapy, may also be enrolled. Parts A and B * Has HCV RNA ≥ 10,000 IU/mL in peripheral blood at enrollment. * Has either absence of cirrhosis or presence of compensated cirrhosis. * If female, be not of reproductive potential or agree to avoid becoming pregnant beginning at least 2 weeks prior to administration of the initial dose of study drug, through either 6 months \[Part A\] or 14 days \[Part B\] after taking the last dose of study drug (or longer if dictated by local regulations), by complying with one of the following: (1) practice abstinence from heterosexual activity or (2) use (or have their partner use) two forms of acceptable contraception during heterosexual activity which may include oral contraceptives. * For HIV co-infected participants: 1) have documented HIV-1 infection \[Part A\] or HIV infection \[Part B\]; 2) either not be currently on antiretroviral therapy (ART) with no plans to initiate ART while participating in this study or have well controlled HIV on ART; and 3) have at least one viable antiretroviral regimen alternative beyond their current regimen in the event of HIV virologic failure and the development of anti-retroviral drug resistance \[Part A\].
Exclusion criteria
Part A * Has previously received a DAA containing regimen other than the permitted regimens listed above. * Did not complete their prior DAA therapy due to intolerance to the DAA regimen or who failed the DAA regimen for reasons other than relapse (e.g., virologic breakthrough, rebound or non-response, non-compliance, lost to follow-up, withdrew consent). * Is a male whose female partner(s) is/are pregnant or is a male who is expecting to donate sperm or planning to impregnate female partner(s) from at least two weeks prior to Day 1 through at least 6 months after last dose of study drug, or longer if dictated by local regulations. * Has personal or family history of Torsade de pointes. * Has chronic pulmonary disease. * Has an hemoglobinopathy. * Has central nervous system (CNS) trauma requiring intubation, intracranial pressure monitoring, brain meningeal or skull surgery, or resulting in seizure, coma, permanent neurologic deficits, abnormal brain imaging, or cerebral spinal fluid (CSF) leak; prior brain hemorrhage and/or intracranial aneurysms (whether adequately repaired or not). * Has current or history of seizure disorder unless seizure was \>10 years ago, a single isolated event, no history of or current use of anti-seizure medications, and a documented normal neurological examination at Day 1. * Has history of stroke or transient ischemic attack. Part B * Did not complete their prior DAA therapy due to intolerance to the DAA regimen or who failed the DAA regimen for reasons other than virologic failure. * Has any major medical condition, clinically-significant illness (other than HCV), pretrial laboratory or ECG abnormality, or history of any illness that might interfere with treatment, assessment, compliance or pose additional risk in administering study drug to the participant. Parts A and B * Is under the age of legal consent, is mentally or legally incapacitated, has significant emotional problems at the time of pre-study screening visit or expected during the conduct of the study or has a history of a clinically significant psychiatric disorder which, in the opinion of the investigator, would interfere with the study procedures. * Has evidence of decompensated liver disease manifested by the presence of or history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver disease. * Has cirrhosis classified as Child-Pugh Class B or C or has a Pugh-Turcotte score \>6 * Is co-infected with hepatitis B virus (HBV) * For participants with HIV, has a history of opportunistic infection in the 6 months prior to screening. * Has a history of malignancy ≤5 years prior to enrollment except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is under evaluation for other active or suspected malignancy. * Has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC. * Is currently participating or has participated in a study with an investigational compound within 30 days of signing informed consent and is not willing to refrain from participating in another such study during the course of this study (trial treatment period). Participants participating in MK-5172-017 (NCT01667081) may be enrolled in this study, MK- 3682-021. * Has clinically-relevant drug or alcohol abuse within 12 months of screening * Is a female and is pregnant or breastfeeding or expecting to conceive or donate eggs from at least 2 weeks prior to Day 1 through at least 6 months \[Part A\] or 14 days \[Part B\] after last dose of study drug, or longer if dictated by local regulations. * Has organ transplants (including hematopoietic stem cell transplants) other than cornea and hair. * Has history of gastric surgery or history of malabsorption disorders. * Has current or history of any clinically significant cardiac abnormalities/dysfunction. * Has medical/surgical conditions that may result in a need for hospitalization during the period of the study. * Has a medical condition requiring, or likely to require, chronic systemic administration of corticosteroids, tumor necrosis factor (TNF) antagonists, or other immunosuppressant drugs during the course of the study * Has evidence of history of chronic hepatitis not caused by HCV. Participants with history of acute non-HCV-related hepatitis, that resolved \>6 months before study entry, may be enrolled.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12) | 12 weeks following final dose of study treatment ([MK-3682B + RBV Groups]: Study Week 28; [MK-3682B Groups]: Study Week 36) | The percentage of participants achieving SVR12 was determined, defined as having a plasma HCV ribonucleic acid (RNA) level below the lower limit of quantification (LLOQ) 12 weeks after the end of study therapy. Plasma HCV RNA level was measured using the Roche COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay with a LLOQ of 15 IU/mL. |
| Number of Participants Who Experienced an Adverse Event | Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26) | The number of participants experiencing an adverse event (AE) was assessed. An AE is any unfavorable and unintended medical occurrence, symptom, or disease witnessed in a participant, regardless of whether or not a causal relationship with the study treatment can be demonstrated. Further, any worsening of a preexisting condition that is temporally associated with the use of the study treatment is also considered an AE. |
| Number of Participants Who Discontinued Study Drug Due to an Adverse Event | Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26) | The number of participants discontinuing study drug due to an AE was assessed. |
| Number of Participants Who Experienced a Serious Adverse Event | Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26) | The number of participants experiencing a serious adverse event (SAE) was assessed. An SAE is an adverse event that: results in death; is life threatening; results in persistent or significant disability or incapacity; results in or prolongs a hospitalization; is a congenital anomaly or birth defect; is a cancer; or may jeopardize the participant, potentially require medical or surgical intervention. |
| Number of Participants Who Experienced a Drug-Related Adverse Event | Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26) | The number of participants experiencing a drug-related AE was assessed. A drug-related AE was an AE thought to be possibly, probably, or definitely related to the study drug as determined by the investigator. |
| Number of Participants Who Experienced a Serious and Drug-Related Adverse Event | Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26) | The number of participants experiencing a serious and drug-related AE was assessed. |
| Number of Participants Who Experienced an Accidental or Intentional Overdose Without Adverse Effect | Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26) | The number of participants experiencing an accidental or intentional overdose without adverse effect was determined. Per study protocol, any occurrence of a participant receiving either MK-3682B or RBV at any dose higher than prescribed was considered an overdose. If this definition of overdose was met without any associated clinical symptoms or abnormal laboratory results, this occurrence of overdose was reported as an accidental or intentional overdose without adverse effect. |
| Number of Participants Who Experienced a Non-Overdose Event of Clinical Interest | Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26) | The number of participants experiencing a non-overdose event of clinical interest (ECI) was determined. Non-overdose ECIs, assessed from initiation of study therapy through 14 days following study treatment cessation, included the following: 1) aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>500 IU/L; or 2) AST or ALT \>3x nadir value and \>3X upper limit normal (ULN). |
| Number of Participants Who Experienced AST/ALT >5x Upper Limit Normal (ULN) | From Study Week 4 up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26) | The number of participants experiencing AST / ALT \>5 times ULN from study week 4 until 2 weeks following completion of study therapy was determined. |
Participant flow
Recruitment details
For study Part A, 94 cirrhotic (C) or non-cirrhotic (NC) participants with chronic hepatitis C virus (HCV) genotype (GT) 1 previously failing a direct-acting antiviral regimen (DAA) were randomized, with 1 participant withdrawing prior to receiving study treatment. The trial was terminated prior to participant enrollment for study Part B.
Participants by arm
| Arm | Count |
|---|---|
| [Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 \[50 mg\]) + UPR (MK-3682 \[225 mg\]) + RZR (MK-8408 \[30 mg\]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks. | 35 |
| [Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 \[50 mg\]) + UPR (MK-3682 \[225 mg\]) + RZR (MK-8408 \[30 mg\]), administered as 2 tablets once daily for 24 weeks. | 36 |
| [Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 \[50 mg\]) + UPR (MK-3682 \[225 mg\]) + RZR (MK-8408 \[30 mg\]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks. | 9 |
| [Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 \[50 mg\]) + UPR (MK-3682 \[225 mg\]) + RZR (MK-8408 \[30 mg\]), administered as 2 tablets once daily for 24 weeks. | 13 |
| Total | 93 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 1 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 2 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | [Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV | [Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B | [Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV | [Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B | Total |
|---|---|---|---|---|---|
| Age, Continuous | 59.1 years STANDARD_DEVIATION 8.4 | 58.9 years STANDARD_DEVIATION 6.6 | 57.3 years STANDARD_DEVIATION 8.5 | 53.9 years STANDARD_DEVIATION 11 | 58.1 years STANDARD_DEVIATION 8.2 |
| Sex: Female, Male Female | 4 Participants | 2 Participants | 3 Participants | 4 Participants | 13 Participants |
| Sex: Female, Male Male | 31 Participants | 34 Participants | 6 Participants | 9 Participants | 80 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 35 | 0 / 36 | 0 / 9 | 0 / 13 |
| other Total, other adverse events | 29 / 35 | 25 / 36 | 9 / 9 | 12 / 13 |
| serious Total, serious adverse events | 3 / 35 | 4 / 36 | 0 / 9 | 1 / 13 |
Outcome results
Primary
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
The number of participants discontinuing study drug due to an AE was assessed.
Time frame: Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26)
Population: All randomized participants in Part A receiving ≥1 dose of study treatment. Part B was terminated prior to participant enrollment and was not included for analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| [Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV | Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 0 Participants |
| [Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B | Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 0 Participants |
| [Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV | Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 0 Participants |
| [Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B | Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 0 Participants |
Primary
Number of Participants Who Experienced a Drug-Related Adverse Event
The number of participants experiencing a drug-related AE was assessed. A drug-related AE was an AE thought to be possibly, probably, or definitely related to the study drug as determined by the investigator.
Time frame: Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26)
Population: All randomized participants in Part A receiving ≥1 dose of study treatment. Part B was terminated prior to participant enrollment and was not included for analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| [Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV | Number of Participants Who Experienced a Drug-Related Adverse Event | 23 Participants |
| [Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B | Number of Participants Who Experienced a Drug-Related Adverse Event | 18 Participants |
| [Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV | Number of Participants Who Experienced a Drug-Related Adverse Event | 9 Participants |
| [Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B | Number of Participants Who Experienced a Drug-Related Adverse Event | 5 Participants |
Primary
Number of Participants Who Experienced an Accidental or Intentional Overdose Without Adverse Effect
The number of participants experiencing an accidental or intentional overdose without adverse effect was determined. Per study protocol, any occurrence of a participant receiving either MK-3682B or RBV at any dose higher than prescribed was considered an overdose. If this definition of overdose was met without any associated clinical symptoms or abnormal laboratory results, this occurrence of overdose was reported as an accidental or intentional overdose without adverse effect.
Time frame: Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26)
Population: All randomized participants in Part A receiving ≥1 dose of study treatment. Part B was terminated prior to participant enrollment and was not included for analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| [Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV | Number of Participants Who Experienced an Accidental or Intentional Overdose Without Adverse Effect | 1 Participants |
| [Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B | Number of Participants Who Experienced an Accidental or Intentional Overdose Without Adverse Effect | 3 Participants |
| [Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV | Number of Participants Who Experienced an Accidental or Intentional Overdose Without Adverse Effect | 2 Participants |
| [Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B | Number of Participants Who Experienced an Accidental or Intentional Overdose Without Adverse Effect | 1 Participants |
Primary
Number of Participants Who Experienced an Adverse Event
The number of participants experiencing an adverse event (AE) was assessed. An AE is any unfavorable and unintended medical occurrence, symptom, or disease witnessed in a participant, regardless of whether or not a causal relationship with the study treatment can be demonstrated. Further, any worsening of a preexisting condition that is temporally associated with the use of the study treatment is also considered an AE.
Time frame: Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26)
Population: All randomized participants in Part A receiving ≥1 dose of study treatment. Part B was terminated prior to participant enrollment and was not included for analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| [Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV | Number of Participants Who Experienced an Adverse Event | 31 Participants |
| [Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B | Number of Participants Who Experienced an Adverse Event | 27 Participants |
| [Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV | Number of Participants Who Experienced an Adverse Event | 9 Participants |
| [Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B | Number of Participants Who Experienced an Adverse Event | 12 Participants |
Primary
Number of Participants Who Experienced a Non-Overdose Event of Clinical Interest
The number of participants experiencing a non-overdose event of clinical interest (ECI) was determined. Non-overdose ECIs, assessed from initiation of study therapy through 14 days following study treatment cessation, included the following: 1) aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>500 IU/L; or 2) AST or ALT \>3x nadir value and \>3X upper limit normal (ULN).
Time frame: Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26)
Population: All randomized participants in Part A receiving ≥1 dose of study treatment. Part B was terminated prior to participant enrollment and was not included for analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| [Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV | Number of Participants Who Experienced a Non-Overdose Event of Clinical Interest | 0 Participants |
| [Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B | Number of Participants Who Experienced a Non-Overdose Event of Clinical Interest | 1 Participants |
| [Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV | Number of Participants Who Experienced a Non-Overdose Event of Clinical Interest | 0 Participants |
| [Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B | Number of Participants Who Experienced a Non-Overdose Event of Clinical Interest | 0 Participants |
Primary
Number of Participants Who Experienced a Serious Adverse Event
The number of participants experiencing a serious adverse event (SAE) was assessed. An SAE is an adverse event that: results in death; is life threatening; results in persistent or significant disability or incapacity; results in or prolongs a hospitalization; is a congenital anomaly or birth defect; is a cancer; or may jeopardize the participant, potentially require medical or surgical intervention.
Time frame: Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26)
Population: All randomized participants in Part A receiving ≥1 dose of study treatment. Part B was terminated prior to participant enrollment and was not included for analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| [Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV | Number of Participants Who Experienced a Serious Adverse Event | 3 Participants |
| [Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B | Number of Participants Who Experienced a Serious Adverse Event | 4 Participants |
| [Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV | Number of Participants Who Experienced a Serious Adverse Event | 0 Participants |
| [Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B | Number of Participants Who Experienced a Serious Adverse Event | 1 Participants |
Primary
Number of Participants Who Experienced a Serious and Drug-Related Adverse Event
The number of participants experiencing a serious and drug-related AE was assessed.
Time frame: Up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26)
Population: All randomized participants in Part A receiving ≥1 dose of study treatment. Part B was terminated prior to participant enrollment and was not included for analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| [Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV | Number of Participants Who Experienced a Serious and Drug-Related Adverse Event | 0 Participants |
| [Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B | Number of Participants Who Experienced a Serious and Drug-Related Adverse Event | 0 Participants |
| [Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV | Number of Participants Who Experienced a Serious and Drug-Related Adverse Event | 0 Participants |
| [Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B | Number of Participants Who Experienced a Serious and Drug-Related Adverse Event | 0 Participants |
Primary
Number of Participants Who Experienced AST/ALT >5x Upper Limit Normal (ULN)
The number of participants experiencing AST / ALT \>5 times ULN from study week 4 until 2 weeks following completion of study therapy was determined.
Time frame: From Study Week 4 up to 2 weeks following cessation of study treatment ([MK-3682B + RBV Groups]: Up to Week 18; [MK-3682B Groups]: Up to Week 26)
Population: All randomized participants in Part A receiving ≥1 dose of study treatment with ≥1 AST/ALT measurement subsequent to study week 4. One participant with prior SOF/LDV failure receiving MK-3682B + RBV withdrew from study before study week 4 and was excluded from analysis. Part B terminated prior to enrollment and was not included for analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| [Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV | Number of Participants Who Experienced AST/ALT >5x Upper Limit Normal (ULN) | 0 Participants |
| [Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B | Number of Participants Who Experienced AST/ALT >5x Upper Limit Normal (ULN) | 0 Participants |
| [Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV | Number of Participants Who Experienced AST/ALT >5x Upper Limit Normal (ULN) | 0 Participants |
| [Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B | Number of Participants Who Experienced AST/ALT >5x Upper Limit Normal (ULN) | 0 Participants |
Primary
Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12)
The percentage of participants achieving SVR12 was determined, defined as having a plasma HCV ribonucleic acid (RNA) level below the lower limit of quantification (LLOQ) 12 weeks after the end of study therapy. Plasma HCV RNA level was measured using the Roche COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay with a LLOQ of 15 IU/mL.
Time frame: 12 weeks following final dose of study treatment ([MK-3682B + RBV Groups]: Study Week 28; [MK-3682B Groups]: Study Week 36)
Population: All randomized participants in Part A receiving ≥1 dose of study treatment. Part B was terminated prior to participant enrollment and was not included for analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| [Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV | Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12) | 97.1 Percentage |
| [Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B | Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12) | 100.0 Percentage |
| [Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV | Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12) | 100.0 Percentage |
| [Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B | Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12) | 100.0 Percentage |